Last reviewed · How we verify
EXDENSUR (DEPEMOKIMAB-ULAA)
EXDENSUR (generic name: DEPEMOKIMAB-ULAA) is a drug developed by GLAXOSMITHKLINE LLC. It is currently FDA-approved.
Depemokimab-ulaa binds to IL-5, blocking its interaction with the IL-5 receptor and reducing eosinophil activity.
EXDENSUR is an antibody that inhibits Interleukin-5, a molecular target. It is classified as an inhibitor and is used to target Interleukin-5.
At a glance
| Generic name | DEPEMOKIMAB-ULAA |
|---|---|
| Sponsor | GLAXOSMITHKLINE LLC |
| Target | IL-5 |
| Therapeutic area | Other |
| Phase | FDA-approved |
Mechanism of action
Depemokimab-ulaa is a monoclonal antibody that targets IL-5, a key cytokine involved in eosinophil function. By binding to IL-5, it prevents the cytokine from interacting with its receptor on eosinophils, leading to reduced eosinophil growth, survival, and activation. This helps decrease inflammation associated with conditions like asthma.
Approved indications
Common side effects
- Upper respiratory tract infection
- Allergic rhinitis
- Influenza
- Arthralgia
- Pharyngitis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXDENSUR CI brief — competitive landscape report
- EXDENSUR updates RSS · CI watch RSS
- GLAXOSMITHKLINE LLC portfolio CI
Frequently asked questions about EXDENSUR
What is EXDENSUR?
How does EXDENSUR work?
Who makes EXDENSUR?
What is the generic name of EXDENSUR?
What development phase is EXDENSUR in?
What are the side effects of EXDENSUR?
What does EXDENSUR target?
Related
- Target: All drugs targeting IL-5
- Manufacturer: GLAXOSMITHKLINE LLC — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing